Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Misoprostol-oxytocin combination versus carbetocin for prevention of postpartum hemorrhage after vaginal delivery
PACTR202501843286396Phase 3Recruiting
- Sponsor
- Dr. Ogudugu Festus Ayobami O.
- Start
- Aug 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postpartum hemorrhage (PPH) comparing Misoprostol + oxytocin with Carbetocin + placebo (2 arms). Primary endpoint: Mean blood loss. Started Aug 2024; status: recruiting.
02
Drugs
misoprostoloxytocincarbetocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202501843286396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202501843286396.